Why a candidate reached a large trial
Researchers had reasons to investigate creatine in relation to cellular energy and neurological injury. Earlier screening studies did not rule it out as a candidate worth testing further. That is an intermediate research decision, not proof that a treatment works. A compound can pass an early screen and fail a later, more definitive clinical test.
The NINDS Exploratory Trials in Parkinson Disease program selected creatine for a long-term study designed to assess clinical progression. The relevant question was whether it improved outcomes in people with early, treated Parkinson's disease compared with placebo. This was a disease-specific question, distinct from strength training or general supplement marketing.
Our monohydrate explanation covers the ingredient's basic identity. Recognizing an ingredient's name or a plausible mechanism does not tell a reader the answer to a clinical trial in a different condition.
Who participated in the long-term study
The trial reported in JAMA in 2015 enrolled 1,741 participants across 45 sites in the United States and Canada. They had early Parkinson's disease and were already receiving dopaminergic treatment. Participants were assigned to creatine monohydrate or placebo, with the study designed around longer-term follow-up.
Existing Parkinson's therapy continued, and treatment adjustments were permitted. Creatine was therefore not being tested as a substitute for established care. Describing the trial as simply asking whether creatine helps the brain would omit the diagnosed population, the treatment background and the particular outcomes the researchers selected.
The number enrolled should also be distinguished from the number contributing to a particular interim analysis. The analysis that led to stopping concerned 955 participants enrolled early enough to be eligible for five-year follow-up. Median follow-up across the study was four years. It would be inaccurate to say that every one of the 1,741 participants completed five years of treatment.
Clinical decline was assessed across several measures
The main statistical test combined information from five measures addressing disability, daily activities, walking capacity, cognition and Parkinson's-related quality of life. This approach was intended to capture clinical decline more broadly than one isolated laboratory result.
The trial did not demonstrate improvement in its principal clinical comparison with creatine. A claim about muscle energy, a favorable result from a different disease study, or a person's impression after using a supplement cannot replace that result. Each belongs to a different kind of evidence.
For comparison, our diabetes research article examines a separate population and outcome. The fact that an ingredient is investigated in more than one condition does not mean favorable findings can be transferred between them.
What stopping for futility means
The study included planned interim analyses and an independent safety-monitoring process. At the relevant analysis, the results met the specified criteria for considering an early stop because continuing was unlikely to establish the intended benefit. The monitoring board recommended termination, and NINDS accepted that recommendation in 2013.
Futility is a research term about the likelihood of demonstrating the planned effect under the trial's design and observed results. It should not be translated into a claim that every conceivable use of creatine has been disproved. It also should not be softened into an implication that the trial was simply unfinished and therefore remains positive evidence for Parkinson's treatment.
The published authors concluded that the findings did not support creatine monohydrate use for the tested Parkinson's context. That negative clinical result is the relevant conclusion when a seller invokes neuroprotection or disease progression. An early-stage rationale cannot be presented as if the later trial never happened.
Laboratory monitoring had its own complications
The full report describes concerns that creatine affected the usefulness of blood creatinine and creatinine-based kidney estimates for safety monitoring. Investigators changed eligibility and stopping rules during the study. This is a reminder that a laboratory number needs the context of supplement use and the person's clinical situation.
It is not a reason for readers to dismiss a concerning kidney result as harmless. Nor does it establish that every change in creatinine means kidney damage. Our kidney blood-test guide explains why the clinician needs the full history and appropriate assessment rather than an assumption based on a supplement label.
The trial did not detect certain between-group adverse-event differences under its stated analysis. That finding does not certify universal safety for people outside its eligibility criteria, people using different combinations, or every duration of use. The clinical and monitoring limits remain separate from the absence of demonstrated disease benefit.
What was available for this review
We accessed the full primary report through PubMed Central after the PubMed extraction was blocked. The article identifies NINDS funding and describes the funder's involvement in design, conduct and reporting. It also lists author consulting and research relationships; this publication does not label the study free of all potential conflicts.
We read the report's design, results, monitoring discussion and disclosures. We did not obtain individual participant data, independently audit the trial or calculate a new treatment effect. The published evidence is strong enough to prevent an unsupported disease-slowing claim without pretending that this article has reproduced the investigators' analysis.
A product review cannot substitute for neurological care
The Strong Suit review records the currently advertised powder and purchase plans. Neither a plain monohydrate formula nor a quality claim establishes that the finished product treats Parkinson's disease. A commercial first position on this site contributes no clinical evidence to that question.
NINDS describes Parkinson's care as individualized and involving established medical and supportive approaches. Questions about a supplement should go to the treating team with the exact label and the reason for considering it. Do not change prescribed treatment or delay evaluation because an advertisement uses energy or brain-health language.
The pulmonary-rehabilitation article offers another example of a plausible muscle-related idea that needed a direct clinical test. Across both topics, keeping the eventual trial result visible is more useful than repeating only why the ingredient once looked promising.